D. E. Shaw & Co., Inc. Nuvation Bio Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Nuvation Bio Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 860,940 shares of NUVB stock, worth $2.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

860,940

Previous 514,930 67.2%

Holding current value

$2.52 Million

Previous $777,000 303.22%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.46 - $3.97 $505,174 - $1.37 Million	346,010 Added 67.2%	860,940 $3.13 Million
Q4 2023 Feb 14, 2024	BUY	$0.96 - $1.53 $429,080 - $683,847	446,959 Added 657.57%	514,930 $777,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $2.1 $55,773 - $92,956	-44,265 Reduced 39.44%	67,971 $91,000
Q2 2023 Aug 14, 2023	BUY	$1.56 - $1.84 $50,754 - $59,864	32,535 Added 40.82%	112,236 $202,000
Q1 2023 May 15, 2023	SELL	$1.6 - $2.48 $61,712 - $95,653	-38,570 Reduced 32.61%	79,701 $132,000

Q4 2022 Feb 14, 2023	SELL	$1.68 - $2.5 $168,930 - $251,385	-100,554 Reduced 45.95%	118,271 $227,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $20,621 - $287,284	71,110 Added 48.14%	218,825 $490,000
Q2 2022 Aug 15, 2022	BUY	$3.24 - $5.85 $372,395 - $672,381	114,937 Added 350.65%	147,715 $479,000
Q1 2022 May 16, 2022	SELL	$4.6 - $8.83 $171,083 - $328,405	-37,192 Reduced 53.15%	32,778 $172,000
Q4 2021 Feb 14, 2022	SELL	$7.75 - $10.05 $740,287 - $959,986	-95,521 Reduced 57.72%	69,970 $595,000
Q3 2021 Nov 15, 2021	SELL	$7.78 - $10.0 $26,638 - $34,240	-3,424 Reduced 2.03%	165,491 $1.65 Million
Q2 2021 Aug 16, 2021	BUY	$9.22 - $14.48 $1.56 Million - $2.45 Million	168,915 New	168,915 $1.57 Million

Others Institutions Holding NUVB

# of Institutions

126

Shares Held

107M

Call Options Held

40.6K

Put Options Held

2.9K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $637M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account